CN115279349A - 奥美卡替莫卡必尔片剂 - Google Patents

奥美卡替莫卡必尔片剂 Download PDF

Info

Publication number
CN115279349A
CN115279349A CN202180013878.7A CN202180013878A CN115279349A CN 115279349 A CN115279349 A CN 115279349A CN 202180013878 A CN202180013878 A CN 202180013878A CN 115279349 A CN115279349 A CN 115279349A
Authority
CN
China
Prior art keywords
weight
tablet formulation
tablet
omeprazole
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180013878.7A
Other languages
English (en)
Chinese (zh)
Inventor
M.毕
Y-H.姜
H.楼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN115279349A publication Critical patent/CN115279349A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CN202180013878.7A 2020-02-10 2021-02-10 奥美卡替莫卡必尔片剂 Pending CN115279349A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972506P 2020-02-10 2020-02-10
US62/972,506 2020-02-10
PCT/US2021/017429 WO2021163172A1 (en) 2020-02-10 2021-02-10 Omecamtiv mecarbil tablet

Publications (1)

Publication Number Publication Date
CN115279349A true CN115279349A (zh) 2022-11-01

Family

ID=74858801

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180013878.7A Pending CN115279349A (zh) 2020-02-10 2021-02-10 奥美卡替莫卡必尔片剂

Country Status (9)

Country Link
US (1) US20230090391A1 (enExample)
EP (1) EP4103159A1 (enExample)
JP (1) JP7696353B2 (enExample)
CN (1) CN115279349A (enExample)
AU (1) AU2021221106A1 (enExample)
BR (1) BR112022015457A2 (enExample)
CA (1) CA3168513A1 (enExample)
IL (1) IL295490A (enExample)
WO (1) WO2021163172A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161617A1 (en) * 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
WO2014152198A1 (en) * 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
CN105120844A (zh) * 2013-03-14 2015-12-02 美国安进公司 杂环化合物和其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161617A1 (en) * 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
WO2014152198A1 (en) * 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
CN105120844A (zh) * 2013-03-14 2015-12-02 美国安进公司 杂环化合物和其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAMESHRAJA PALAPARTHY 等: "Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects", 《INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS》, vol. 54, no. 03, pages 217 - 227, XP055797640, DOI: 10.5414/CP202458 *

Also Published As

Publication number Publication date
CA3168513A1 (en) 2021-08-19
WO2021163172A1 (en) 2021-08-19
BR112022015457A2 (pt) 2022-10-04
US20230090391A1 (en) 2023-03-23
JP7696353B2 (ja) 2025-06-20
JP2023513249A (ja) 2023-03-30
EP4103159A1 (en) 2022-12-21
IL295490A (en) 2022-10-01
AU2021221106A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP7696353B2 (ja) オメカムチブメカルビル製剤
US20120232156A1 (en) Controlled release dosage forms
CA2795324C (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EP3130355A1 (en) Pharmaceutical composition containing pregabalin with improved stability and method for preparing same
JP2004518676A (ja) 最小化ｐＨ依存性溶解プロフィールを有する徐放性薬学的剤形
CN102036656A (zh) 含有蜡的缓释制剂
JP2012516299A (ja) 有機化合物のガレヌス製剤
US9387166B2 (en) Controlled release oral dosage form comprising oxycodone
US20160287541A1 (en) Modified Release Tranexamic Acid Formulation
JP2021518423A (ja) レナリドミドの経口用コーティング錠剤組成物
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
US20080139514A1 (en) Diphosphonic acid pharmaceutical compositions
WO2020175897A1 (ko) 미라베그론 또는 그의 약제학적으로 허용되는 염을 함유한 방출조절 제제
US11510878B2 (en) Extended release multiparticulates of ranolazine
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
EP3796908B1 (en) Controlled release propiverine formulations
WO2009027786A2 (en) Matrix dosage forms of varenicline
CN101090738A (zh) 含有碱性药物或其盐的基质型缓释制剂及其制备方法
JP2004339072A (ja) 優れた安定性を有するプラバスタチンナトリウム固形製剤
US20080182908A1 (en) Pharmaceutical compositions comprising memantine
JP2021518424A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
RU2839277C1 (ru) Новая композиция замедленного высвобождения тофацитиниба, его производных и солей
WO2023044024A1 (en) Novel ph dependent coating drug delivery system
CA2461168A1 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
WO2021116244A1 (en) Modulation of drug release and bioavailability of compositions containing dolutegravir sodium and other anti hiv drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination